OTCMKTS:ENZN - Enzon Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.23 0.00 (0.00 %)
(As of 04/25/2019 04:00 PM ET)
Previous Close$0.23
Today's Range$0.23 - $0.24
52-Week Range$0.1901 - $0.2910
Volume52,200 shs
Average Volume42,755 shs
Market Capitalization$10.17 million
P/E RatioN/A
Dividend YieldN/A
Beta0.23
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron for use in the treatment of chronic hepatitis C; and Sylatron for use in the treatment of melanoma disease. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

Receive ENZN News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolOTCMKTS:ENZN
Previous SymbolNASDAQ:ENZN
CUSIP29390410
Phone732-980-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.92 million
Cash Flow$0.1307 per share
Book Value$0.34 per share

Profitability

Net Income$5.85 million

Miscellaneous

EmployeesN/A
Market Cap$10.17 million
Next Earnings Date5/9/2019 (Estimated)
OptionableNot Optionable

Enzon Pharmaceuticals (OTCMKTS:ENZN) Frequently Asked Questions

What is Enzon Pharmaceuticals' stock symbol?

Enzon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ENZN."

How were Enzon Pharmaceuticals' earnings last quarter?

Enzon Pharmaceuticals Inc (OTCMKTS:ENZN) announced its earnings results on Wednesday, August, 10th. The biotechnology company reported $0.02 earnings per share for the quarter. The biotechnology company had revenue of $2.27 million for the quarter. View Enzon Pharmaceuticals' Earnings History.

When is Enzon Pharmaceuticals' next earnings date?

Enzon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Enzon Pharmaceuticals.

Has Enzon Pharmaceuticals been receiving favorable news coverage?

News headlines about ENZN stock have trended somewhat positive this week, InfoTrie reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Enzon Pharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.

Who are some of Enzon Pharmaceuticals' key competitors?

What other stocks do shareholders of Enzon Pharmaceuticals own?

Who are Enzon Pharmaceuticals' key executives?

Enzon Pharmaceuticals' management team includes the folowing people:
  • Mr. Andrew Rackear, CEO & Sec. (Age 65)
  • Mr. Richard L. Feinstein, VP of Fin. & CFO (Age 76)

How do I buy shares of Enzon Pharmaceuticals?

Shares of ENZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzon Pharmaceuticals' stock price today?

One share of ENZN stock can currently be purchased for approximately $0.23.

How big of a company is Enzon Pharmaceuticals?

Enzon Pharmaceuticals has a market capitalization of $10.17 million and generates $6.92 million in revenue each year.

What is Enzon Pharmaceuticals' official website?

The official website for Enzon Pharmaceuticals is http://www.enzon.com.

How can I contact Enzon Pharmaceuticals?

Enzon Pharmaceuticals' mailing address is 20 Commerce Drive Suite 135, Cranford NJ, 07016. The biotechnology company can be reached via phone at 732-980-4500 or via email at [email protected]


MarketBeat Community Rating for Enzon Pharmaceuticals (OTCMKTS ENZN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  81 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  138
MarketBeat's community ratings are surveys of what our community members think about Enzon Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENZN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/25/2019 by MarketBeat.com Staff

Featured Article: What is the S&P 500 Index?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel